
Influencer Files Case Against The Whole Truth Brand, Claims It Is Misleading. Brand Calls His Claim Misleading
In today's world, consumers are often confused about what's safe or healthy to eat. With an overload of information online, it's easy to get overwhelmed and be unsure of what to consume and when.
If you search the Internet, you'll find the answer you're looking for, no matter the bias. If you look up 10 reasons why a particular food is bad, you'll easily find 20 more justifying why you shouldn't eat it. Conversely, if you want 10 reasons why that same food should be added to your diet, the Internet will give you that too.
To escape this vicious cycle, you might think of shopping offline instead-going to the grocery store yourself. But the experience isn't any better. With hundreds of ingredients on every shelf and the pressure to read every label, the process remains just as exhausting.
So, when a brand launches in the Indian market promising simple ingredients and transparent labelling, there's little doubt it'll do well. One such brand, now valued at Rs 2,133 crore, is The Whole Truth.
Yes, we're talking about The Whole Truth, launched in 2019. In case you're unaware, it's a clean-label food brand focused on transparency and honesty in its ingredients. It was initially launched as "And Nothing Else" and later rebranded to better reflect its commitment to full ingredient disclosure.
What Happened?
Things took a turn for the worse when influencer Akash Yadav, also known as Akash Yadhuvanshi, filed a complaint against the brand for allegedly misleading consumers.
With over three lakh Instagram followers, Akash filed the complaint with FSSAI (Food Safety and Standards Authority of India) and followed it up with a video on his social media.
In the video, Akash says that although his content doesn't usually focus on such topics, he felt compelled to speak when "a brand that claims to be clean" falls short of what they promise.
View this post on Instagram
A post shared by Akash Yadav (@sir_akash_yaduvanshi)
"I generally don't make such videos, but when you eat clean, work out, avoid junk, and then a brand promising 'no lies' ends up serving you half-truths, you feel bad. I don't want drama, but I've filed a case against the brand," he says in the video.
Akash recalls that when he first came across the brand, he was excited -- it seemed honest, had a bold tagline, and looked legit. But after doing some digging, he says he found red flags.
The Protein Powder Problem
Akash first points to their protein powder, which he claims has excessive sugar. For instance, The Whole Truth's coffee-flavoured protein powder contains 25 grams of sugar per 100 grams, of which 14 grams is added.
He argues that an ideal protein powder should have 0-5 grams of sugar. Experts seem to mostly agree.
Komal Malik, a dietitian at Asian Hospital, Haryana, says, "Generally, complete protein powders don't include sugar as they're isolated. But some do add flavour enhancers, which can contain sugar." She agrees that 25 grams of sugar per 100 grams "does sound like a lot".
Akash also criticises the brand's claim that the powder is for "everyone", saying the added sugar makes it unsuitable for kids, diabetics, and those avoiding sugar.
Debjani Gupta, Functional Nutritionist and Founder of Wellness For All, disagrees. She says she has personally used the product and had no issues with it.
"This protein powder is beginner-friendly, and that explains the sugar. If someone wants a no-sugar option, they can go for the Whey Isolate version," she says.
Akash raises similar concerns about the brand's protein bars, suggesting they are not truly for "everyone".
The Hazelnut Spread
Another issue he points out is with their Hazelnut Spread. Akash claims the brand advertises it as being made with real chocolate, but says it actually uses "cocoa nibs and cocoa powder, which is not real chocolate".
Debjani partially agrees. She clarifies that while cocoa nibs and cocoa powder are both derived from cacao beans and are processed, the processing isn't necessarily bad for your health.
This is because real chocolate -- i.e., cocoa -- is high in fat and antioxidants, but also bitter in taste. Processing it (to make cocoa powder and cocoa nibs) not only improves the taste slightly but also reduces the fat content, which is important if you're trying to manage your weight. However, this also means that some antioxidants are lost in the process.
"Cocoa nibs are roasted and crushed cacao beans, while cocoa powder is processed further, sometimes using alkalisation," she explains.
She adds that cocoa nibs and cocoa powder offer a rich, chocolatey flavour and are a healthier alternative to processed chocolate; being high in antioxidants, fibre, and healthy fats.
"Cocoa nibs and cocoa powder are a healthier option for those trying to eat clean. Instead of calories from sugar and artificial flavours, you're getting denser nutrients and mindful calories. That said, moderation is still key," she adds.
"So, I decided to file the complaint because I don't think the brand is providing the clarity it's supposed to," Akash concludes.
Akash also shared with NDTV, that the brand changed their tagline and removed the bit about how their protein bar is for 'your parents and your kids', soon after the video was released.
Have a look:
The before and the after. Photo: The Whole Truth
How The Brand And Internet Reacted
Akash's video, posted a week ago, sparked mixed reactions. While some supported him, others disagreed.
Here's how The Whole Truth responded:
The brand posted a detailed comment directly addressing Akash.
"Dear Akash, I am Shashank, founder of The Whole Truth. All three of your points are baseless, as I'll explain below. Yet you chose to make this video instead of waiting for our response-your complaint hasn't even reached us," he wrote.
Shashank clarified that the protein powder in question is their "Beginner's Protein".
"It has 15 grams of protein and 4.3 grams of added sugar (from jaggery) per scoop. That's one teaspoon of sugar, clearly declared on the front of the pack. The phrase 'protein for everyone' means it's not just for gym freaks -- it's for people starting their protein journey who need balanced macros," he explained.
The Whole Truth was founded by Shashank Mehta in 2019. Photo: The Whole Truth
He also mentioned that for serious fitness users, they offer products with 24-30 grams protein and 0 gram added sugar.
"Yet you highlighted only the beginner range and exaggerated the sugar content by quoting per 100 grams, which is nearly 3x the scoop size. That's misleading," he added.
On the protein bar, the brand says it never claimed to be for "everyone" and calls that assertion false.
Lastly, Shashank defends the hazelnut spread, saying it does contain real chocolate.
"I know, because we make our own chocolate. Cocoa nibs and cocoa powder are both pure chocolate ingredients. In fact, it's a regulatory requirement to declare them as such," he added.
"This should clarify things. Your followers deserve accurate facts, not misleading numbers and false claims," he concluded.
So, was Akash simply chasing attention, or does the brand need to relook its messaging? You decide.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Print
3 minutes ago
- The Print
In battle for Indian anti-obesity market, Eli Lilly's pre-filled pen on one side, Novo Nordisk's on other
The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation for Mounjaro in the KwikPen presentation, Eli Lilly said in a statement Thursday, adding that the approval marks an important step in advancing care for people living with type 2 diabetes and obesity in India. Mounjaro by US-based Eli Lilly & Company, which has tirzepatide as its active pharmaceutical ingredient (API), was launched in India on 20 March this year in vial format, which meant it was more cumbersome to administer. New Delhi: Eli Lilly India, makers of the obesity drug Mounjaro, said Thursday that they have received approvals from the Indian regulator for their pre-filled pen, a day after competitor Novo Nordisk's global mega-selling drug for obesity, Wegovy, hit the Indian markets. The pens offer a convenient way for patients to take their medication. First developed as a treatment for type 2 diabetes in lower doses, both Mounjaro and Wegovy are weekly injections intended to dramatically reduce weight in obese patients. They have emerged as global sensations in the pharmaceutical market world over, with their sales reaching multi-billion-dollar figures. These drugs have also been fighting to dominate the obesity management space in many developed countries. They are now aiming to capture a share of the market in India, where obesity is growing rapidly, driven by changing dietary and lifestyle patterns. India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore, and is projected to grow nearly eightfold to Rs 25,000 crore by 2030, according to market estimates. A 2023 survey by the Indian Council of Medical Research (ICMR) and Madras Diabetes Research Foundation (MDRF) had shown that 25.4 crore Indians, or 28.6 percent, of the population had generalised obesity. Obesity, now recognised as a chronic, relapsing disease, is a major risk factor for diabetes and is linked to over 200 health complications, including hypertension, dyslipidemia or high blood cholesterol, coronary heart disease, and obstructive sleep apnea. Also Read: Fat-busting drug Mounjaro launched in India. Here's how much it will cost Promise of simplified treatment KwikPen, or Mounjaro, is a multi-dose, prescription-based, single-patient-use pre-filled pen designed for once-weekly administration, the company said. It also added that the full range of doses for Mounjaro—2.5 mg to 15 mg—will be available in India soon, supporting personalised treatment as recommended by treating physicians. Earlier, the vial format of the drug was launched in only two dosage strengths—2.5 mg and 5 mg—in the country. The latest announcement came after Wegovy, which has semaglutide as its API, got a strategic launch in India as an innovative, easy-to-use pre-filled pen called FlexTouch devices. It was aimed at stealing the thunder Mounjaro had by reaching Indian patients first. A less potent version of semaglutide, in the form of an oral pill-under the brand name of Rybelsus, has been available in India since 2022 for the treatment of diabetes. The Wegovy pre-filled pen has been launched in five dosing strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. While the monthly cost of the first three dosages is Rs 17,345, the higher doses will cost Rs 24,280 and Rs 26,050, respectively. Mounjaro, in the vial format, was launched at a cost of Rs 14,000 (for 2.5 mg) and Rs 17,500. Eli Lilly, however, has yet to decide the price of the Mounjaro KwikPen for all five dosages. Meanwhile, experts ThePrint spoke to said pre-filled pens will simplify treatment, making these powerful anti-obesity and diabetes medications more convenient for patients. 'With simplified administration, adherence improves, helping more individuals achieve better weight and metabolic health outcomes,' explained Mumbai-based diabetologist Dr Rajiv Kovil. Senior diabetologist and researcher Dr V. Mohan also said this could make a profound impact on the lives of lakhs of people in India. Mounjaro vs Wegovy—which is more effective Both tirzepatide and semaglutide, the prescription-only drugs, mimic the effects of natural gut hormones that work by lowering caloric intake, primarily by influencing appetite control mechanisms. Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, while semaglutide functions as a mono GLP-1 receptor agonist. Both GIP and GLP-1 are natural incretin hormones, that stimulate a decrease in blood glucose levels, found in brain regions that regulate appetite. In May this year, Lilly said in a statement that a head-to-head clinical trial comparing tirzepatide and semaglutide in their maximum tolerable doses showed the former to be significantly more effective than the latter in reducing both weight and waist circumference after 72 weeks of treatment. According to the US-based pharma giant, participants administered tirzepatide saw an average weight reduction of 20.2 percent, while those on semaglutide experienced a 13.7 percent loss—indicating a 47 percent greater relative weight loss for the former, based on the treatment regimen estimated at 72 weeks. But one advantage that semaglutide has in the higher dose strength is its ability to also treat several other metabolic conditions, such as cardiovascular diseases and kidney disorders. While Mounjaro is better than Wegovy in percentage of weight loss, there is stronger evidence in the case of Wegovy for reducing cardiovascular conditions in obese people without diabetes and also for treating kidney and diabetes, experts said. During the launch of Wegovy on 24 June, Novo Nordisk underlined that the drug is the only medication approved in India for treating major adverse cardiovascular events (MACE), along with obesity. Diabetologist Kovil said, 'If there is an obese patient who does not have other major underlying issues yet, I will be more inclined towards prescribing Mounjaro.' He added that, in patients with comorbidities such as diabetes, liver or kidney disorder or cardiovascular condition, Wegovy could be a better choice as it reduces mortality and improves longevity. In response to queries by ThePrint, Eli Lilly said that Mounjaro offers a novel approach to metabolic health management, giving treating physicians an innovative option for treating both diabetes and obesity. 'Ultimately, it is up to physicians to determine the most appropriate treatment based on individual patient needs and clinical judgment,' said the drugmaker. According to Dr Ambrish Mithal, chairman and head, endocrinology and diabetes with Max Healthcare, anti-obesity drugs can be indicated for people with a BMI (Body Mass Index) of 30 and above in the absence of other comorbidities. However, in people with other pre-existing conditions, either of the drugs can be initiated at a BMI of 27 and above, in conjunction with diet, lifestyle changes and under expert supervision, he said. Experts also warn about the possible side effects of GLP-1 agonist drugs amid concerns around misuse of these drugs in India, given the regulatory loopholes which allow patients to access most prescription drugs over the counter. Large clinical trials and post-marketing evidence following use of these medicines have shown that while nausea, bloating, vomiting and diarrhoea are comparatively mild side effects of these medications. In rare cases, they can also cause stomach paralysis, a disorder that affects the normal movement of the stomach muscles. In a response to queries by ThePrint, Eli Lilly emphasised that Mounjaro is a prescription-only drug and should be taken strictly under a doctor's supervision. 'Tirzepatide is not approved for, and should not be used for, cosmetic weight loss or by individuals under 18. Lilly neither promotes nor encourages the unapproved use of tirzepatide by anyone,' the company said. (Edited by Sanya Mathur) Also Read: Mounjaro will shrink India's appetite for packaged food, gyms, weight loss supplements


Time of India
16 minutes ago
- Time of India
Ayurveda's FMCG share remains low despite rising household use
Ayurveda, India's traditional healthcare system, accounts for just over 1% of the country's overall fast-moving consumer goods (FMCG) market despite leading companies launching hundreds of natural and herbal personal care products over the past few years. While 92% of Indian households purchased ayurvedic products in 2024-25 compared to 89% five years ago, the contribution of the segment to the total FMCG volume increased to 1.1% from 0.8% during the period, according to a new exclusive report by Kantar, consumer insights arm of WPP. Moreover, in 2024-25, sales of ayurvedic products by volume fell 1% year-on-year, its first decline ever, a sharp reversal from the high double-digit growth in recent years on the back of the meteoric rise of Patanjali, an Ayurveda-based brand by yoga guru Baba Ramdev and the Covid-19 pandemic-driven affinity for natural products. "Ayurvedic brands grew during the pandemic as consumers shifted focus on immunity. But most brands talk about natural ingredients and not many companies talk about ayurveda. In FY24, Patanjali drove the category growth and in FY25, their performance dragged the numbers down. While there are temporary hiccups, there is interest in the sector," said K Ramakrishnan, managing director, South Asia, Worldpanel Division. "While not falling under the traditional FMCG bracket, products with ingredients such as ashwagandha, triphala, shilajit are selling D2C (direct-to-consumer) and even on Q-Comm (quick commerce) channels, reaching the urban upper sections of society." Ayurvedic brands are those which use traditional principles and methods of ayurveda, while natural brands just add a few natural or herbs to their products. Dabur 's sales increased 3% year-on-year in 2024-25, Himalaya and Cholayil expanded 7.5% and 1.3%, respectively. However, sales of both Patanjali and Vicco fell 4% year-on-year, impacting the overall segment growth, said Kantar. "We have been taking steps to drive penetration of our healthcare brands and expanding the need state beyond immunity by getting into new areas like combating stress, digestion etc., besides expanding the consumer cohorts and increasing usage occasions. These have helped our key Ayurvedic brands maintain their momentum and record market share gains," said Dabur CEO Mohit Malhotra. He added that the company continued to add new products and offer age-old ayurvedic remedies in modern formats to better connect with the millennial consumers. Almost every household in India purchases at least one ayurvedic brand. with Dabur having the highest penetration (81%), followed by Patanjali (58%), according to Kantar. However, Patanjali, due to its presence across many categories, dominates with a higher volume share.


India Gazette
16 minutes ago
- India Gazette
Tripura CM virtually inaugurates, lays foundation stone of infrastructure and healthcare projects in Sepahijala district
Sepahijala (Tripura) [India], June 26 (ANI): Tripura Chief Minister Manik Saha on Thursday virtually inaugurated and laid the foundation stone of several key infrastructure and healthcare projects at Bishalgarh in Sepahijala district. 'Infrastructure development is underway across Tripura. As part of this initiative, today I virtually inaugurated 7 new Ayushman Arogya Mandir buildings in Sepahijala district from an event held at Bishalgarh Town Hall,' Saha said in a post on X. The post said, 'Additionally, laid the foundation stones for the following 5 projects---Bishalgarh SDM Office building at a cost of Rs 8.10 crore, new building for Bishalgarh Hospital at a cost of Rs 2.10 crore, an upgraded 8 km road from Bishalgarh to Golaghati at a cost of Rs 11 crore and the DCM quarters in Bishramganj at a cost of Rs 2 crore and the SDM quarters in Bishalgarh at a cost of Rs 83 lakh.' The event marked a significant push toward improved administrative and healthcare facilities in the region. The Chief Minister also virtually inaugurated seven new buildings under the Ayushman Arogya initiative, further strengthening the state's healthcare infrastructure. The event also witnessed the distribution of NOAS (Notification of Ayushman Scheme) certificates to Microsapara PHC, Dayarampara Yubarajghat, and Ujan Pathalia Ayushman Arogya Mandirs, formalising their inclusion in the state's flagship health mission. Furthermore, certificates were awarded to several villages for being declared as Child Marriage Free Villages, underlining the state government's ongoing commitment to social reform and child protection. Speaking at the event, CM Saha emphasised the government's vision for holistic development, focusing on administrative efficiency, road connectivity, and accessible healthcare for all. 'These projects will not only strengthen the administrative setup but also provide quality healthcare and infrastructure for the people of Sepahijala,' CM Saha stated. The ceremony was attended by local residents, officials, and party workers, who welcomed the developments as a step forward in the region's growth story. (ANI)